Compounds > s 0139
Page last updated: 2024-08-03 19:17:17

s 0139

Description

S 0139: structure given in first source; ET(A) receptor antagonist [MeSH]

Cross-References

ID SourceID
PubMed CID54687463
MeSH IDM0229104

Synonyms (8)

Synonym
S-0139 ,
cxq71t7yty ,
162117-90-0
s 0139
olean-12-en-28-oic acid, 27-(((2e)-3-(2-(((2e)-3-carboxy-1-oxo-2-propenyl)amino)-5-hydroxyphenyl)-1-oxo-2-propenyl)oxy)-3-oxo-, sodium salt (1:2)
unii-cxq71t7yty
olean-12-en-28-oic acid, 27-((3-(2-((3-carboxy-1-oxo-2-propenyl)amino)-5-hydroxyphenyl)-1-oxo-2-propenyl)oxy)-3-oxo-, disodium salt, (27(e(e)))-
sb-737004

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's13 (61.90)18.2507
2000's6 (28.57)29.6817
2010's2 (9.52)24.3611
2020's0 (0.00)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.55%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (95.45%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
creatine
1
glycine derivative;
guanidines;
zwitterion		geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical		1999199925.0low001000
5-dimethylamiloride
1
2001200123.0low000100
indomethacin
2
aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic		1995199529.0low002000
oleanolic acid
21
hydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite1994201024.4high0015600
amiloride
1
aromatic amine;
guanidines;
organochlorine compound;
pyrazines		diuretic;
sodium channel blocker		2001200123.0low000100
fluorescein
1
2-benzofurans;
gamma-lactone;
organic heteropentacyclic compound;
oxaspiro compound;
polyphenol;
xanthene dye		fluorescent dye;
radioopaque medium		1999199925.0low001000
bosentan anhydrous
1
primary alcohol;
pyrimidines;
sulfonamide		antihypertensive agent;
endothelin receptor antagonist		1995199529.0low001000
1h-indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1s,2r,3s)-
1
1995199529.0low001000
bq 123
1
cyclic peptide1994199430.0low001000
dinoprostone
5
prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic		1995199927.8low005000
leukotriene b4
2
dihydroxy monocarboxylic acid;
hydroxy polyunsaturated fatty acid;
leukotriene;
long-chain fatty acid		human metabolite;
mouse metabolite;
plant metabolite;
vasoconstrictor agent		1997199926.0low002000
myriceron caffeoyl ester
1
1994199430.0medium001000
mocetinostat
1
aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent		2001200123.0low000100
losartan potassium
1
1999199925.0low001000
s6c sarafotoxin
4
1995200027.5low004000
endothelin-1
8
1995201023.8medium005300
piperidines
2
1999200124.0low001100
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Anterior Circulation Transient Ischemic Attack0
2
1998200124.5low001100
Apoplexy0
1
2002200222.0low000100
Brain Edema0
1
2001200123.0low000100
Brain Swelling0
1
2001200123.0low000100
Cardiac Failure0
1
2000200024.0low001000
Cardiac Hypertrophy0
1
2000200024.0low001000
Cardiomegaly0
1
2000200024.0low001000
Cerebral Infarction, Middle Cerebral Artery0
2
2001200819.5low000200
Chronic Kidney Failure0
1
1999199925.0low001000
Decerebrate Posturing0
1
1994199430.0low001000
Disease Models, Animal0
3
1998200124.7low002100
Heart Disease, Ischemic0
1
2001200123.0low000100
Heart Failure0
1
2000200024.0low001000
Hemorrhage, Subarachnoid0
2
1998199925.5low002000
Infarction, Middle Cerebral Artery0
2
2001200819.5low000200
Inflammation0
1
1997199727.0low001000
Injury, Ischemia-Reperfusion0
1
2001200123.0low000100
Innate Inflammatory Response0
1
1997199727.0low001000
Intraocular Pressure0
4
1995199628.8medium004000
Ischemic Attack, Transient0
2
1998200124.5low001100
Kidney Failure, Chronic0
1
1999199925.0low001000
Myocardial Ischemia0
1
2001200123.0low000100
Proteinuria0
1
1999199925.0low001000
Reperfusion Injury0
1
2001200123.0low000100
Stroke0
1
2002200222.0low000100
Subarachnoid Hemorrhage0
2
1998199925.5low002000
Uveitis, Anterior0
1
1999199925.0low001000

Pharmacokinetics (1)

ArticleYear
Prolonged pharmacodynamic effects of S-0139, an intravenously administered endothelin A (ET) antagonist, in the human forearm blood flow model.
British journal of clinical pharmacology, , Volume: 69, Issue:3		2010

Dosage (3)

ArticleYear
Prolonged pharmacodynamic effects of S-0139, an intravenously administered endothelin A (ET) antagonist, in the human forearm blood flow model.
British journal of clinical pharmacology, , Volume: 69, Issue:3		2010
Profiles of an intravenously available endothelin A-receptor antagonist, S-0139, for preventing cerebral vasospasm in a canine two-hemorrhage model.
Life sciences, , Volume: 63, Issue:4		1998
The effects of ETB receptor-selective agonist on IOP and blood-aqueous barrier in rabbit eyes: role of cyclooxygenase products.
Japanese journal of ophthalmology, , Volume: 39, Issue:4		1995